NK/T cell lymphoma Recent advances. Y.L Kwong University Department of Medicine Queen Mary Hospital
|
|
- Paulina Kelley
- 5 years ago
- Views:
Transcription
1 NK/T cell lymphoma Recent advances Y.L Kwong University Department of Medicine Queen Mary Hospital
2 Natural killer cell lymphomas NK cell lymphomas are mainly extranodal lymphomas Clinical classification 1. Nasal 2. Non-nasal 3. Disseminated (leukaemia / lymphoma)
3 Typical lesion lethal midline granuloma
4 Typical lesion lethal midline granuloma
5 Non-nasal NK/T-cell lymphomas
6 Cutaneous NK cell lymphoma Arm Scrotum
7 Cutaneous NK cell lymphoma
8 Extranasal NK-cell lymphoma
9 CNS NK cell lymphoma
10 Cutaneous NK cell lymphoma
11 Cutaneous NK cell lymphoma and mosquito bite hypersensitivity
12 Cutaneous NK cell lymphoma, nasal type
13 Cutaneous NK/T cell lymphoma, nasal type Disseminated NK cell lymphoma
14 Recent advances in NK/T-cell lymphomas 1. Advent of L-asparaginase containing regimens 2. Plasma EBV DNA quantification in monitoring of response 3. PET/CT as an integral part of the management 4. Prognostication of NK/T-cell lymphoma 5. Optimal sequencing of chemotherapy and radiotherapy 6. Immunotherapy of NK/T-cell lymphomas
15 Recent advances in NK/T-cell lymphomas 1. Advent of L-asparaginase containing regimens 2. Plasma EBV DNA quantification in monitoring of response 3. PET/CT as an integral part of the management 4. Prognostication of NK/T-cell lymphoma 5. Optimal sequencing of chemotherapy and radiotherapy 6. Immunotherapy of NK/T-cell lymphomas
16 Problems of treatment 1. NK/T-cell lymphomas are radiosensitive. However, about 50% of patients treated with radiotherapy alone will relapse, of whom about half relapse systemically, indicating that the disease is not really localized. Therefore, NK/T-cell lymphoma should never be treated with radiotherapy alone 2. Conventional chemotherapy designed for B cell lymphomas does not work very well for NK cell lymphomas. Anthracyclines have not been shown to be necessary in NK cell lymphomas 3. NK cells express the highest amount of P- glycoprotein, leading to the multidrug resistance phenotype
17 NK/T-cell lymphomas treated by CHOP Chim et al, Blood 2004
18 SMILE protocol for NK cell lymphomas (K. Oshimi) 2 g/m 2 Methotrexate Folinic acid Daily MTX level 1.5g/m 2 Ifosfamide mesna 40mg/d Dexamethasone 100mg/m 2 etoposide 6000u/m 2 /d L-asparaginase G-CSF Days
19 SMILE protocol for NK cell lymphomas (K. Oshimi) 2 g/m 2 Methotrexate Folinic acid Daily MTX level 1.5g/m 2 Ifosfamide mesna 40mg/d Dexamethasone 100mg/m 2 etoposide 6000u/m 2 /d L-asparaginase G-CSF Days
20 SMILE: phase II results
21 SMILE: results outside clinical trial
22 SMILE in 87 cases of NK/T-cell lymphomas Overall survival: newly-diagnosed Kwong et al, Blood 2012
23 Survivals of NK/T-cell lymphomas SMILE (all stages) CHOP (stage I/II)
24 Non MDR related chemotherapy Promace-CytaBOM (III) DHAP (I) SMILE (II)
25 Non MDR related chemotherapy Promace-CytaBOM (III) + RT SMILE (II)
26 Second generation non-mdr dependent regimens Kwong & Tse, Blood 2013
27 Second generation non-mdr dependent regimens Kwong & Tse, Blood 2013
28 Recent advances in NK/T-cell lymphomas 1. Advent of L-asparaginase containing regimens 2. Plasma EBV DNA quantification in monitoring of response 3. PET/CT as an integral part of the management 4. Prognostication of NK/T-cell lymphoma 5. Optimal sequencing of chemotherapy and radiotherapy 6. Immunotherapy of NK/T-cell lymphomas
29 Circulating EBV DNA 1. Plasma EBV DNA 2. Whole blood EBV DNA Cellular EBV DNA + plasma EBV DNA
30 Plasma versus whole blood for EBV DNA Plasma whole blood Conceptual DNA plasma plasma and WBC Origin tumor tumor and EBV + B-cells Contamination none EBV + B-cells PCR competitor Nil WBC genomic DNA Standard WHO none Comparison Quantification per ml variable (per mg DNA) Inter-laboratory possible impossible
31 For quantification of circulating EBV DNA as a monitoring for EBV+ lymphomas Plasma EBV DNA is the suitable starting material Whole blood should not be used
32 Plasma versus PBMNC for EBV DNA
33 Plasma versus PBMNC for EBV DNA
34 Source of positive specimens (%) Plasma versus PBMNC for EBV DNA Positive in PBMC Positive in Plasma Indeterminate Positive in PBMC + Plasma EBV+ disease (N=105) EBV+ disease in CR (N=18) No EBV+ disease (N=402)
35 Quantification of circulating EBV DNA for prognostication and assessment of minimal residual disease
36 Plasma EBV DNA
37 Plasma EBV DNA
38 Presentation EBV DNA for SMILE treated NK/T-cell lymphoma
39 Impact of negative EBV DNA after SMILE (I) on OS Kwong et al Leukemia 2014
40 Impact of dynamic EBV DNA changes on DFS Kwong et al Leukemia 2014
41 Conclusions 1. Presentation EBV DNA reflects tumor load, but does not impact on survivals 2. Negative EBV DNA after SMILE (I) reflects superior response to chemotherapy, and therefore impacts on OS 3. For patients already in CR, nondetectable EBV DNA means optimal suppression of tumor cells, and therefore impacts on DFS
42 Recent advances in NK/T-cell lymphomas 1. Advent of L-asparaginase containing regimens 2. Plasma EBV DNA quantification in monitoring of response 3. PET/CT as an integral part of the management 4. Prognostication of NK/T-cell lymphoma 5. Optimal sequencing of chemotherapy and radiotherapy 6. Immunotherapy of NK/T-cell lymphomas
43 Deauville five-point scale for interim PET 1. No uptake. 2. Uptake mediastinum. 3. Uptake > mediastinum but liver. 4. Uptake moderately increased compared to the liver at any site. 5. Uptake markedly increased compared to the liver at any site or/and new sites of disease.
44 Deauville criteria for end of treatment PET 1. Category 1: score 1, 2, 3 likely to represent complete metabolic response (CMR) 2. Category 2: score 4 with reduction of intensity from baseline, but no new lesions, representing partial metabolic response (PMR) at interim but residual metabolic disease (RMD) at end of treatment 3. Category 3: score 5 with no significant reduction in uptake or new lesions at interim, or score 4 or 5 with increase in uptake in previous foci and/or new FDGavid foci consistent with lymphoma, representing no metabolic response or progressive metabolic disease (NMR/PMD)
45 Role of interim PET/CT in SMILE therapy
46 Role of interim PET/CT in SMILE therapy Khong et al J Nucl Med 2014
47 Role of interim PET/CT in SMILE therapy Multivariate analysis OS Deauville 5-point score P < Multivariate analysis PFS Deauville 5-point score P < 0.001
48 Impact of mid-treatment PET/CT on OS Khong et al J Nucl Med 2014
49 Impact of mid-treatment PET/CT on PFS Khong et al J Nucl Med 2014
50 Impact of end-of-treatment PET/CT on OS Khong et al J Nucl Med 2014
51 Impact of end-of-treatment PET/CT and EBV DNA
52 Combined EBV DNA and PET/CT at end of treatment Prognostic impact Kim et al Lancet Haematol 2015
53 Combined EBV DNA and PET/CT at end of treatment Prognostic impact Kim et al Lancet Haematol 2015
54 EBV DNA and PET/CT scan Interim results should be evaluated Inability to achieve a molecular or radiologic remission is associated with poor treatment outcome Prospective data needed to define what the best approach is for poor interim results
55 Recent advances in NK/T-cell lymphomas 1. Advent of L-asparaginase containing regimens 2. Plasma EBV DNA quantification in monitoring of response 3. PET/CT as an integral part of the management 4. Prognostication of NK/T-cell lymphoma 5. Optimal sequencing of chemotherapy and radiotherapy 6. Immunotherapy of NK/T-cell lymphomas
56 Prognostic factors for ENKT EBV DNA PET/CT KIPI PINK PINK-E
57 Prognostic factors for ENKT EBV DNA PET/CT KIPI PINK PINK-E
58 PINK / PINK-E : prognostication Age Stage Non-nasal type Distant lymph-node involvement Detectable EBV DNA Established and validated with data from non-anthracycline regimens
59 PINK : prognostication OS DFS Kim et al Lancet Oncol 2016
60 PINK : prognostication OS DFS Kim et al Lancet Oncol 2016
61 PINK - E : prognostication OS DFS Kim et al Lancet Oncol 2016
62 PINK - E : prognostication OS DFS Kim et al Lancet Oncol 2016
63 Recent advances in NK/T-cell lymphomas 1. Advent of L-asparaginase containing regimens 2. Plasma EBV DNA quantification in monitoring of response 3. PET/CT as an integral part of the management 4. Prognostication of NK/T-cell lymphoma 5. Optimal sequencing of chemotherapy and radiotherapy 6. Immunotherapy of NK/T-cell lymphomas
64 Concurrent chemotherapy and radiotherapy
65 Survival of patients induced by concomitant chemotherapy and radiotherapy, and consolidated by L-asparaginse containing regimens
66 SMILE in 87 cases of NK/T-cell lymphomas Overall survival: IPI for prognostication P=0.001 Low High Low-Inter High-Inter Kwong et al Blood 2012
67 The outcome of concomitant or sequential chemotherapy and radiotherapy is comparable Concomitant Chemotherapy & Radiotherapy Sequential Chemotherapy & Radiotherapy
68 The outcome of concomitant or sequential chemotherapy and radiotherapy is comparable Concomitant Chemotherapy & Radiotherapy Sequential Chemotherapy & Radiotherapy
69 NK/T-cell lymphoma, CCRT or CT+RT Background 1. RT conventionally used for stage I/II disease 2. Ineffective CT added to RT did not improve outcome 3. Relapse rate of RT alone reaches 50% 4. CCRT gave apparently better results, in the era of CHOP / CHOP-like regimens 5. In the era of L-asparaginase-containing regimens, results of CT much improved 6. Unclear if CCRT has any significant advantage over CT + RT
70 CT, RT or CCRT for stage I / II Objective 1. Evaluate the efficacy of CT + RT in comparison with CCRT Method 1. Retrospective multi-center study 2. Stage I/II patients 3. Different combinations of CT, RT and CCRT 4. All CT regimens were non-anthracycline ones, most containing L-asparaginase
71 CT, RT or CCRT for stage I / II Results 303 patients from 22 participating centers M: 207 F: 96 Stage I: 207 Stage II: 96 CT : 11% RT : 6% CT + RT : 18% CCRT + CT : 57% RT + CT : 3% CCRT : 6%
72 CT, RT or CCRT for stage I / II Kwong et al Ann Oncol 2018
73 CT, RT or CCRT Kwong et al Ann Oncol 2018
74 CT, RT or CCRT Kwong et al Ann Oncol 2018
75 CT, RT or CCRT for stage I / II Kwong et al Ann Oncol 2018
76 CT, RT or CCRT for stage I / II Conclusions 1. When effective CT is used, the results of CT + RT are comparable with CCRT 2. The position of RT in stage I/II patients is not critical, because most patients will have reached a complete response before receiving RT 3. Efforts should be made to eliminate RT from the treatment algorithm
77 Recent advances in NK/T-cell lymphomas 1. Advent of L-asparaginase containing regimens 2. Plasma EBV DNA quantification in monitoring of response 3. PET/CT as an integral part of the management 4. Prognostication of NK/T-cell lymphoma 5. Optimal sequencing of chemotherapy and radiotherapy 6. Immunotherapy of NK/T-cell lymphomas
78 Immunotherapy for NK/T-cell lymphoma CD56 CD30 CD56 Batlevi et al, Nat Rev Clin Oncol 2016
79 Immunotherapy for NK/T-cell lymphoma CD56 CD30 Batlevi et al, Nat Rev Clin Oncol 2016
80 Brentuximab vedotin in NK/T-cell lymphoma Poon & Kwong Ann Hematol 2016
81 Brentuximab vedotin in NK/T-cell lymphoma Poon & Kwong Ann Hematol 2016
82 Brentuximab vedotin in NK/T-cell lymphoma Poon & Kwong Ann Hematol 2016
83 Brentuximab vedotin in NK/T-cell lymphoma Poon & Kwong Ann Hematol 2016
84 Immunotherapy for NK/T-cell lymphoma Batlevi et al Nat Rev Clin Oncol 2016
85 Case presentation: refractory NKTCL M / 37 Nasal NK/T-cell lymphoma 2007: regional hospital ProMACE-CytaBOM + RT 2013: relapse PIGLETS x : relapse SMILE x 3
86 M / : Massive epistaxis Hemorrhagic shock Aspiration pneumonia Activated factor VII to stop bleeding Tracheostomy to protect airway
87 Case presentation: refractory NKTCL
88 EBV DNA response Pembrolizumab Kwong et al, Blood 2017
89 Targeting of PD1 in NK/T-cell lymphomas Kwong et al, Blood 2017
90 Targeting of PD1 in NK/T-cell lymphomas Kwong et al, Blood 2017
91 Targeting of PD1 in NK/T-cell lymphomas Kwong et al, Blood 2017
92 Targeting of PD1 in NK/T-cell lymphomas CD3 Kwong et al, Blood 2017
93 Targeting of PD1 in NK/T-cell lymphomas CD4 Kwong et al, Blood 2017
94 Targeting of PD1 in NK/T-cell lymphomas CD8 Kwong et al, Blood 2017
95 Targeting of PD1 in NK/T-cell lymphomas EBER Kwong et al, Blood 2017
96 Pseudo-progression during PD1 blockade in NK/T-cell lymphoma Kwong et al, Blood 2017
97 Targeting of PD1 in NK/T-cell lymphomas CASE 2
98 Targeting of PD1 in NK/T-cell lymphomas F / 80 Stage IV NK/T-cell lymphoma CR after L-asparaginase regimen Short CR with disseminated relapse On referral, ECOG score: 4
99 Targeting of PD1 in NK/T-cell lymphomas
100 Targeting of PD1 in NK/T-cell lymphomas
101 Targeting of PD1 in NK/T-cell lymphomas
102 Targeting of PD1 in NK/T-cell lymphomas Nivolumab 40 mg No toxicity in the first cycle Second dose nivolumab 40 mg Tumour lysis syndrome Cytokine release syndrome (with hypofibrinogemia, respiratory impairment)
103 Targeting of PD1 in NK/T-cell lymphomas
104 Targeting of PD1 in NK/T-cell lymphomas All skin lesions disappeared after the tumor lysis syndrome Skin biopsy: complete pathologic remission
105 Targeting of PD1 in NK/T-cell lymphomas Before
106 Targeting of PD1 in NK/T-cell lymphomas Before After
107 Targeting of PD1 in NK/T-cell lymphomas Before
108 Targeting of PD1 in NK/T-cell lymphomas Before After
109 Targeting of PD1 in NK/T-cell lymphomas Before
110 Targeting of PD1 in NK/T-cell lymphomas Before After
111 Targeting of PD1 in NK/T-cell lymphomas H&E CD3 CD4 CD8 EBER pre
112 Targeting of PD1 in NK/T-cell lymphomas H&E CD3 CD4 CD8 EBER pre post
113 Targeting of PD1 in NK/T-cell lymphomas 1. To date, one of the most effective salvage methods for R/R NK/T-cell lymphomas 2. Beware of a. Pseudo-progression b. TLS (in high tumor load cases) C. CRS (in high tumor load cases) 3. Ongoing trials of pembrolizumab and nivolumab 4. Future directions: whether PD1 blockade can substitute RT, and whether PD1 blockade alone is adequate for good-risk patients
114 Recent advances in NK/T-cell lymphomas 1. Frontline chemotherapy should contain L- asparaginase 2. Plasma EBV DNA quantification is useful in disease monitoring. Aim for negative plasma EBV DNA after 2 3 cycles of treatment 3. PET/CT is an integral part of the management. Aim for DS 3 at interim 4. Prognostication of NK/T-cell lymphoma with the PINK / PINK-E scores is needed 5. When effective chemotherapy is used, it does not matter when radiotherapy is used (? even omitted) 6. PD1 blockade is highly effective
115 Acknowledgment NKTSG K. Oshimi, M. Yamaguchi, R. Suzuki ALSG W.S. Kim, S.T. Lim Haematology Team, Queen Mary Hospital
116 Acknowledgement
117 Hematology, Medical Oncology and Hematopoietic stem cell transplantation Queen Mary Hospital, Hong Kong
NK/T cell lymphoma Hong Kong Experience with L-Asparaginase containing regimens. Y.L. Kwong University Department of Medicine Queen Mary Hospital
NK/T cell lymphoma Hong Kong Experience with L-Asparaginase containing regimens Y.L. Kwong University Department of Medicine Queen Mary Hospital Management of NK cell malignancies Principles 1. Accurate
More informationEast Midlands Cancer Network Guidelines for diagnosis and management of mature T cell and NK cell lymphomas (excluding cutaneous T cell lymphoma)
East Midlands Cancer Network Guidelines for diagnosis and management of mature T cell and NK cell lymphomas (excluding cutaneous T cell lymphoma) Written by: Dr Chris Fox with input from Dr Fiona Miall
More informationCurrent treatment approaches for NK/T-cell lymphoma
Journal of clinical and experimental hematopathology Vol. 57 No.2, XXX-XXX, 2017 JC lin EH xp ematopathol Review Article Current treatment approaches for NK/T-cell lymphoma Motoko Yamaguchi, Kana Miyazaki
More informationReview Article Extranodal Natural-Killer/T-Cell Lymphoma, Nasal Type
Hindawi Publishing Corporation Advances in Hematology Volume 2010, Article ID 627401, 5 pages doi:10.1155/2010/627401 Review Article Extranodal Natural-Killer/T-Cell Lymphoma, Nasal Type Harinder Gill,
More informationFDG PET for therapy response assessment in lymphoma: Beyond Lugano Classification
FDG PET for therapy response assessment in lymphoma: Beyond Lugano Classification Yan Xuexian, MD, DABNM Department of Nuclear Medicine and PET, SGH National Cancer Center Singapore Duke-NUS Medical School
More informationLinfoma de Hodgkin. Novos medicamentos. Otavio Baiocchi CRM-SP
Linfoma de Hodgkin Novos medicamentos Otavio Baiocchi CRM-SP 96.074 Hodgkin Lymphoma Unique B-cell lymphoma HRS malignant cells Scattered malignant Hodgkin-Reed-Sternberg (RS) cells in a background of
More informationImmune checkpoint inhibitors in lymphoma. Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust
Immune checkpoint inhibitors in lymphoma Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust Aims How immune checkpoint inhibitors work Success of immune checkpoint
More informationA CME-certified Oncology Exchange Program
A CME-certified Oncology Exchange Program Jointly provided by Potomac Center for Medical Education and Rockpointe Supported by an educational grant from Seattle Genetics, Inc. Re-treatment with BV Bartlett
More informationRelapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage
More informationSandwich Chemotherapy (CT) with Radiotherapy (RT) Improves Outcomes in Patients with Stage I E. Extranodal Natural Killer (NK)/T-cell Lymphomas
DOI:http://dx.doi.org/10.7314/APJCP.2013.14.7.4061 Sandwich Chemotherapy with Radiotherapy Improves Outcomes with Stage I E /II (NK)/T-cell Lymphomas RESEARCH ARTICLE Sandwich Chemotherapy (CT) with Radiotherapy
More informationOriginal Study. Abstract
Original Study Management of Advanced and Relapsed/ Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes Jonathan E. Brammer, 1 Dai Chihara,
More informationNon-Hodgkin lymphoma
Non-Hodgkin lymphoma Non-Hodgkin s lymphoma Definition: - clonal tumours of mature and immature B cells, T cells or NK cells - highly heterogeneous, both histologically and clinically Non-Hodgkin lymphoma
More informationChanging the landscape of treatment in Peripheral T-cell Lymphoma
Changing the landscape of treatment in Peripheral T-cell Lymphoma Luis Fayad Associate Professor MD Anderson Cancer Center Department of Lymphoma and Myeloma 1 6 What is peripheral 2008 WHO CLASSIFICATION
More informationWhat is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin
What is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin Alison Moskowitz, MD Assistant Attending, Lymphoma Service Memorial Sloan Kettering
More informationBendamustine for Hodgkin lymphoma. Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service
Bendamustine for Hodgkin lymphoma Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service Bendamustine in Hodgkin lymphoma Bifunctional molecule Nitrogen mustard component (meclorethamine)
More informationNovember Radiation Oncology Rotation, OHSU NK-T Cell Presentation. David Routman, MS4
November 2014 Radiation Oncology Rotation, OHSU NK-T Cell Presentation David Routman, MS4 Case Report Case - Presentation HPI: 44 y/o M referred to LAC+USC from OSH Originally presented with: Hearing loss
More informationExtranodal natural killer/t-cell lymphoma with long-term survival and repeated relapses: does it indicate the presence of indolent subtype?
VOLUME 47 ㆍ NUMBER 3 ㆍ September 2012 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Extranodal natural killer/t-cell lymphoma with long-term survival and repeated relapses: does it indicate the presence
More informationNavigating Treatment Pathways in Relapsed/Refractory Hodgkin Lymphoma
Welcome to Managing Hodgkin Lymphoma. I am Dr. John Sweetenham from Huntsman Cancer Institute at the University of Utah. In today s presentation, I will be discussing navigating treatment pathways in relapsed
More informationRelapse After Transplant: Next Steps for Patients with Hodgkin Lymphoma
Hi! My name is Alison Moskowitz. I am an attending at Memorial Sloan Kettering Cancer Center within the Lymphoma Department. I am speaking on behalf of ManagingHodgkinLymphoma.com. I will be discussing
More informationEfficacy of gemcitabine combined with oxaliplatin, L asparaginase and dexamethasone in patients with newly diagnosed extranodal NK/T cell lymphoma
1172 Efficacy of gemcitabine combined with oxaliplatin, L asparaginase and dexamethasone in patients with newly diagnosed extranodal NK/T cell lymphoma HONG QIANG GUO 1,2*, LEI LIU 1,2*, XIN FENG WANG
More informationPeripheral T-cell lymphomas (PTCL) Specified and Unspecified. Eric Van Den Neste Cliniques universitaires Saint-Luc Bruxelles
Peripheral T-cell lymphomas (PTCL) Specified and Unspecified Eric Van Den Neste Cliniques universitaires Saint-Luc Bruxelles BHS seminar 12, 07 March 2015 Peripheral T-cell lymphomas (PTCL) Specified and
More informationPractical Application of PET adapted Therapy in Hodgkin Lymphoma
Practical Application of PET adapted Therapy in Hodgkin Lymphoma Matthew Matasar, MD Lymphoma and Adult BMT Services Director, Lymphoma Survivorship Clinic Memorial Sloan Kettering Cancer Center New York,
More informationAHSCT in Hodgkin lymphoma - indication and challenges. Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital
AHSCT in Hodgkin lymphoma - indication and challenges Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital AHSCT in Hodgkin Lymphoma The role of AHSCT in HL Mobilisation failure
More informationDr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta
Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and
More informationPET-imaging: when can it be used to direct lymphoma treatment?
PET-imaging: when can it be used to direct lymphoma treatment? Luca Ceriani Nuclear Medicine and PET-CT centre Oncology Institute of Southern Switzerland Bellinzona Disclosure slide I declare no conflict
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationWhat are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
More informationISSN: (Print) (Online) Journal homepage:
Hematology ISSN: (Print) 1607-8454 (Online) Journal homepage: https://www.tandfonline.com/loi/yhem20 Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy
More informationTreatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review
Kim et al. Journal of Hematology & Oncology (2018) 11:140 https://doi.org/10.1186/s13045-018-0687-0 REVIEW Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review Seok Jin
More informationAlexander Fosså, M.D. PhD.
Alexander Fosså, M.D. PhD. Current position: Senior Consultant, Department of Medical Oncology Oslo University Hospital Focus of work: - Malignant lymphoma - Chemotherapy, immunotherapy, radiotherapy -
More informationLancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:
1 Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma: 2018-19 1.1 Pretreatment evaluation The following tests should be performed: FBC, U&Es, creat, LFTs, calcium, LDH, Igs/serum
More informationAbstract 861. Stein AS, Topp MS, Kantarjian H, Gökbuget N, Bargou R, Litzow M, Rambaldi A, Ribera J-M, Zhang A, Zimmerman Z, Forman SJ
Treatment with Anti-CD19 BiTE Blinatumomab in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation Abstract
More informationRecent diagnostic and therapeutic innovations of T-cell-lymphoma. Prof. Nossrat Firusian, Recklinghausen, Germany
Recent diagnostic and therapeutic innovations of T-cell-lymphoma Prof. Nossrat Firusian, Recklinghausen, Germany NODAL Angioimmunoblastic T-cell Lymphoma Peripheral T-cell-Lymphoma Anaplastic Large-cell-Lymphoma
More informationABSTRACT. Clinical Research Paper
/, 2016, Vol. 7, (No. 51), pp: 85584-85591 Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal
More informationManagement of high-risk diffuse large B cell lymphoma: case presentation
Management of high-risk diffuse large B cell lymphoma: case presentation Daniel J. Landsburg, MD Assistant Professor of Clinical Medicine Perelman School of Medicine University of Pennsylvania January
More informationPET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma. Ranjana H. Advani, MD
PET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma Ranjana H. Advani, MD Stanford Cancer Institute Management of Hodgkin Lymphoma Learning Objectives Review risk adapted strategies
More informationTreating for Cure or Palliation: Difficult Decisions for Older Adults with Lymphoma
Treating Frail Adults With Common Malignancies: Best Evidence to Personalize Therapy Treating for Cure or Palliation: Difficult Decisions for Older Adults with Lymphoma Raul Cordoba, MD, PhD Lymphoma Unit
More informationPREHYDRATION: 1000 ml NS with potassium chloride 20 meq and magnesium sulphate 2 g IV over 1 hour prior to CISplatin
BC Cancer Protocol Summary for Treatment of Newly Diagnosed Nasal, Extranodal Natural Killer (NK) or T-cell lymphoma, using Concurrent Radiation and weekly CISplatin followed by Etoposide, Ifosfamide,
More informationConfronto Real world e studi registrativi
Confronto Real world e studi registrativi V. Pavone San Giovanni Rotondo 8 Novembre 2018 U.O Ematologia Az.Osp.Card.G.Panico MEDICAL NEED IN HL OUTCOME REDUCE TOXICITY IMPROVE FIRST LINE RISK-ADAPTED STRATEGY
More informationTreatment outcomes of IMEP as a front-line chemotherapy for patients with peripheral T-cell lymphomas
BLOOD RESEARCH VOLUME 51 ㆍ NUMBER 3 September 2016 ORIGINAL ARTICLE Treatment outcomes of IMEP as a front-line chemotherapy for patients with peripheral T-cell lymphomas Ji Young Lee 1, Sang Min Lee 1,
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More information2018 KSMO Immune Oncology Forum. Immune checkpoint inhibitors in hematologic. malignancies: evidences and perspectives 서울아산병원종양내과 홍정용
2018 KSMO Immune Oncology Forum Immune checkpoint inhibitors in hematologic malignancies: evidences and perspectives 서울아산병원종양내과 홍정용 2018-07-18 Contents Introduction Immune checkpoint inhibtors in lymphomas
More informationWhat is the best approach to the initial therapy of PTCL? standards of treatment? Should all
What is the best approach to the initial therapy of PTCL? standards of treatment? hould all Jia Ruan, M.D., Ph.D. Center for Lymphoma and Myeloma Weill Cornell Medical College New York Presbyterian Hospital
More informationSupplementary Appendix to manuscript submitted by Trappe, R.U. et al:
Supplementary Appendix to manuscript submitted by Trappe, R.U. et al: Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful
More informationSarajevo (Bosnia Hercegivina) Monday June :30-16:15. PET/CT in Lymphoma
Sarajevo (Bosnia Hercegivina) Monday June 16 2013 15:30-16:15 PET/CT in Lymphoma FDG-avidity Staging (nodal & extra nodal) Response evaluation Early assessment during treatment / interim (ipet) Remission
More informationAggressive NK-cell leukemia: Therapeutic potentials of L-asparaginase and allogeneic hematopoietic stem cell transplantation
Ishida F/ANKL07 1 Original article Aggressive NK-cell leukemia: Therapeutic potentials of L-asparaginase and allogeneic hematopoietic stem cell transplantation Fumihiro Ishida 1, Young Hyeh Ko 2, Won Seog
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationHigh incidence of false-positive PET scans in patients with aggressive non-hodgkin s lymphoma treated with rituximab-containing regimens
original article 20: 309 318, 2009 doi:10.1093/annonc/mdn629 Published online 7 October 2008 High incidence of false-positive PET scans in patients with aggressive non-hodgkin s lymphoma treated with rituximab-containing
More informationLugano classification: Role of PET-CT in lymphoma follow-up
CAR Educational Exhibit: ID 084 Lugano classification: Role of PET-CT in lymphoma follow-up Charles Nhan 4 Kevin Lian MD Charlotte J. Yong-Hing MD FRCPC Pete Tonseth 3 MD FRCPC Department of Diagnostic
More information8/10/2016. PET/CT for Tumor Response. Staging and restaging Early treatment response evaluation Guiding biopsy
PET/CT for Tumor Response Evaluation August 4, 2016 Wei Lu, PhD Department of Medical Physics www.mskcc.org Department of Radiation Oncology www.umaryland.edu FDG PET/CT for Cancer Imaging Staging and
More informationSMILE (Etoposide, Ifosfamide, Methotrexate and Dexamethasone)
SMILE (Etoposide, Ifosfamide, Methotrexate and Dexamethasone) INDICATION Natural Killer/T-cell lymphoma TREATMENT INTENT Curative SPECIAL PRECAUTIONS This protocol causes marked myelosuppression despite
More informationHistology independent indications in Oncology
CHMP Oncology Working Party Workshop Histology independent indications in Oncology What have we learnt from the anti PD1- PDL1 story? J Camarero (CHMP alternate ES, OncWP) Disclaimers the views presented
More informationWorkshop key imaging questions
11th INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA Lugano, Switzerland, June 15-18, 2011 Workshop key imaging questions Relevance of current imaging staging systems Influence of tumour burden Need for
More informationRadiotherapy improves survival in early stage extranodal natural killer/t cell lymphoma patients receiving asparaginasebased
/, 2017, Vol. 8, (No. 7), pp: 11480-11488 Radiotherapy improves survival in early stage extranodal natural killer/t cell lymphoma patients receiving asparaginasebased chemotherapy Yi-Yang Li 1,2,3,*, Ling-Ling
More informationObjectives. I do not have anything to disclose.
Treatment of APL Objectives I do not have anything to disclose. Objectives 1. Urgency of early recognition and treatment 2. Treatment based on risk stratification 3. Monitoring for relapse 4. Treatment
More informationInt J Clin Exp Med 2018;11(4): /ISSN: /IJCEM
Int J Clin Exp Med 2018;11(4):3235-3244 www.ijcem.com /ISSN:1940-5901/IJCEM0064061 Original Article A retrospective clinical study: combined treatment of chemotherapy and radiotherapy results in optimal
More informationExtranodal natural killer T-cell lymphoma, nasal type, presenting as periorbital cellulitis: A case report
CASE REPORT Miller et al. 1 PEER REVIEWED OPEN ACCESS Extranodal natural killer T-cell lymphoma, nasal type, presenting as periorbital cellulitis: A case report Katherine Miller, Amir Kamran, Anna Koget
More informationPET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationTHE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum
More information2012 by American Society of Hematology
2012 by American Society of Hematology Common Types of HIV-Associated Lymphomas DLBCL includes primary CNS lymphoma (PCNSL) Burkitt Lymphoma HIV-positive patients have a 60-200 fold increased incidence
More informationBrentuximab Vedotin. Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center
Brentuximab Vedotin Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center U.S. Cancer Statistics 2016 300.000 249.260 224.390 200.000 180.890 Incidence 100.000 95.270 76.960
More informationPeripheral T-cell lymphoma. Matt Ahearne Clinical Lecturer, Leicester
Peripheral T-cell lymphoma Matt Ahearne Clinical Lecturer, Leicester PTCL Objectives To understand the natural history of PTCL To appreciate the importance of accurate diagnosis of PTCL including recent
More informationWho should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University
Who should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University Treatment Challenges Several effective options, improve response durations, none curable
More informationAggressive NHL and Hodgkin Lymphoma. Dr. Carolyn Faught November 10, 2017
Aggressive NHL and Hodgkin Lymphoma Dr. Carolyn Faught November 10, 2017 What does aggressive mean? Shorter duration of symptoms Generally need treatment at time of diagnosis Immediate, few days, few weeks
More informationPET-CT in Peripheral T-cell Lymphoma: To Be or Not To Be
PET-CT in Peripheral T-cell Lymphoma: To Be or Not To Be Bruce D. Cheson, M.D. Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington, DC, USA So What is the Question(s)? What is
More informationRichter s Syndrome: Risk, Predictors and Treatment
Richter s Syndrome: Risk, Predictors and Treatment 10/23/2015 John N. Allan MD Assistant Professor of Medicine Division of Hematology and Medical Oncology CLL Research Center Weill Cornell Medicine Agenda
More informationRadiotherapy in aggressive lymphomas. Umberto Ricardi
Radiotherapy in aggressive lymphomas Umberto Ricardi Is there (still) a role for Radiation Therapy in DLCL? NHL: A Heterogeneous Disease ALCL PMLBCL (2%) Burkitt s MCL (6%) Other DLBCL (31%) - 75% of aggressive
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationPositron emission tomography/computed tomography in the diagnosis, staging, and prognostic evaluation of natural killer/t-cell lymphoma
Review Positron emission tomography/computed tomography in the diagnosis, staging, and prognostic evaluation of natural killer/t-cell lymphoma Journal of International Medical Research 2018, Vol. 46(12)
More informationIs there a Role for Upfront Stem Cell Transplantation in Peripheral T-Cell Lymphoma: YES!
Is there a Role for Upfront Stem ell Transplantation in Peripheral T-ell Lymphoma: YES! Norbert Schmitz Dep. Hematology, Oncology and Stem ell Transplantation AK St. Georg Hamburg, Germany OS in the common
More informationJ Clin Oncol 29: by American Society of Clinical Oncology INTRODUCTION
VOLUME 29 NUMBER 33 NOVEMBER 2 211 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural
More informationOutcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers
Tang et al. (2017) 7:653 DOI 10.1038/s41408-017-0030-y CORRESPONDENCE Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers Open
More informationRole of PET in staging and treatment of lymphomas
Role of PET in staging and treatment of lymphomas ESMO preceptorship in lymphoma Lugano, 3-4 November 2017 Martin Hutchings Rigshospitalet, Copenhagen, Denmark EORTC Lymphoma Group PET in lymphoma staging
More informationChemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL
Lymphoma & Myeloma 2015 Chemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL Jeremy S. Abramson, MD Relevant Disclosure Consulting for Seattle
More informationReference: NHS England 1602
Clinical Commissioning Policy Proposition: Clofarabine for refractory or relapsed acute myeloid leukaemia (AML) as a bridge to stem cell transplantation Reference: NHS England 1602 First published: TBC
More informationSummary. Olga Zając, Katarzyna Derwich, Katarzyna Stefankiewicz, Jacek Wachowiak. Rep Pract Oncol Radiother, 2007; 12(5):
Rep Pract Oncol Radiother, 2007; 12(5): 283-288 Preliminary Communication Received: 2007.03.27 Accepted: 2007.07.24 Published: 2007.10.18 Authors Contribution: A Study Design B Data Collection C Statistical
More informationAcute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010
Acute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010 ALL Epidemiology 20% of new acute leukemia cases in adults 5200 new cases in 2007 Most are de novo Therapy-related
More informationKamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA
Kamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA Objectives Describe the current standard approach for patients with relapsed/refractory
More informationToday, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center
Today, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center Today, how many PTCL patients are cured? Some but not as many
More informationBLOOD RESEARCH REVIEW ARTICLE THE HISTORY OF KLWP-CISL INTRODUCTION
BLOOD RESEARCH VOLUME 48 ㆍ NUMBER 3 September 2013 REVIEW ARTICLE Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma
More informationIAN CROCKER = TIM HOWARD
Winship Cancer Institute of Emory University Radiation as Consolidation in the Treatment of Newly Diagnosed CNS Lymphoma versus After Failure of Chemotherapy Pro: Upfront Radiation Ian Crocker MD, FACR,
More informationRole of PET in staging and treatment of lymphomas
Role of PET in staging and treatment of lymphomas ESMO preceptorship in lymphoma Madrid, 25 November 2016 Martin Hutchings Rigshospitalet, Copenhagen, Denmark EORTC Lymphoma Group PET in lymphoma staging
More informationIntegrating FDG PET data for lymphoma management. Michel Meignan, France
Integrating FDG PET data for lymphoma management Michel Meignan, France Combining metabolic data from baseline, interim or post treatment PET PET Data can be combined: 1. Together 2. With baseline clinical
More informationKim et al. Journal of Hematology & Oncology 2013, 6:86
Kim et al. Journal of Hematology & Oncology 2013, 6:86 JOURNAL OF HEMATOLOGY & ONCOLOGY RESEARCH Open Access Extranodal natural killer/t-cell lymphoma involving the gastrointestinal tract: analysis of
More informationRadiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York
Radiotherapy in DLCL is often worthwhile Dr. Joachim Yahalom Memorial Sloan-Kettering, New York The case for radiotherapy Past: Pre-Rituximab randomized trials Present: R-CHOP as backbone, retrospective
More informationLYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center
LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center Lymphoma is cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make up and store cells
More informationUpdates in T cell Lymphoma
Winship Cancer Institute of Emory University Updates in T cell Lymphoma Mary Jo Lechowicz August 2014 Objectives Update current care for patients with Peripheral T cell Non Hodgkin lymphomas (PTCL) upfront
More informationABSTRACT INTRODUCTION
/, Vol. 6, No. 30 Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase Liang Wang 1,2,*, Hua Wang
More informationBleomycin versus Brentuximab in Hodgkin Lymphoma: Don t Hold Your Breath
Bleomycin versus Brentuximab in Hodgkin Lymphoma: Don t Hold Your Breath Rachel Bubik, PharmD, BCPS PGY-2 Hematology/Oncology Pharmacy Resident January 8 th, 2019 2017 MFMER slide-1 Objectives 1. Explain
More informationPeripheral T-Cell Lymphoma. Pro auto. Peter Reimer. Klinik für Hämatologie / intern. Onkologie und Stammzelltransplantation
Peripheral T-Cell Lymphoma Pro auto Peter Reimer Klinik für Hämatologie / intern. Onkologie und Stammzelltransplantation Kliniken Essen Süd, Evang. Krankenhaus Essen-Werden ggmbh COSTEM, Berlin 09.09.2011
More informationTherapeutic Radiology and Oncology, 2018
Original Article Page 1 of 9 Preliminary study of integrating pretreatment and early followup FDG-PET in patients with localized nasal natural killer/t-cell lymphoma receiving concurrent chemoradiotherapy
More informationDERBY-BURTON LOCAL CANCER NETWORK FILENAME SMILE.DOC CONTROLLED DOC NO: HCCPG B57 CSIS Regimen Name: SMILE. SMILE chemotherapy
SMILE chemotherapy Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Extranodal
More informationThe Importance of PET/CT in Human Health. Homer A. Macapinlac, M.D.
The Importance of PET/CT in Human Health Homer A. Macapinlac, M.D. Learning objectives Provide an overview of the impact of PET/CT imaging on the management of patients and its impact on health care expenditures.
More informationIs there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes
Is there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes Bertrand Coiffier Service d Hématologie Hospices Civils de Lyon Equipe «Pathologie
More informationBrentuximab, Nivolumab: L esperienza Real Word della REP. Dr.ssa Clara De Risi Az. Osp. Card. G. Panico - Tricase
Brentuximab, Nivolumab: L esperienza Real Word della REP Dr.ssa Clara De Risi Az. Osp. Card. G. Panico - Tricase MEDICAL NEED IN HL OUTCOME REDUCE TOXICITY IMPROVE FIRST LINE RISK-ADAPTED STRATEGY IMPROVE
More informationWhich is the best treatment for relapsed APL?
Which is the best treatment for relapsed APL? 7th International Symposium on Acute Promyelocytic Leukemia, Rome, September 24 27, 2017 Eva Lengfelder Department of Hematology and Oncology University Hospital
More informationAggressive B-cell lymphomas and gene expression profiling towards individualized therapy?
Aggressive B-cell lymphomas and gene expression profiling towards individualized therapy? Andreas Rosenwald Institute of Pathology, University of Würzburg, Germany Barcelona, June 18, 2010 NEW WHO CLASSIFICATION
More informationHodgkin. The PET World. Sally Barrington
Hodgkin The PET World Sally Barrington PET-CT Staging in HL PET-CT changes stage 15-30% RATHL - Advanced HL 1171 pts Stage by PET-CT compared with cect and BMB 20% stage change; upstaging 14% Most upstaging
More informationMantle Cell Lymphoma
Mantle Cell Lymphoma Clinical Case A 56 year-old woman complains of pain and fullness in the left superior abdominal quadrant for the last 8 months. She has lost 25 kg, and lately has had night sweats.
More information